|
Video: What is a Stock Split?
|
|
BioAtla is a clinical-stage biopharmaceutical company developing its antibody-based therapeutics for the treatment of solid tumor cancer. Co.'s conditionally active biologics (CAB) capitalize on its proprietary discoveries with respect to tumor biology, enabling Co. to target known and validated tumor antigens. Co.'s CAB therapeutic candidates exploit characteristic pH differences between the tumor microenvironment and healthy tissue. Unlike healthy tissue, the tumor microenvironment is acidic and has designed its antibodies to selectively bind to their targets on cancer cells under acidic pH conditions but not on targets in normal tissues. According to our BioAtla stock split history records, BioAtla has had 0 splits. | |
|
BioAtla (BCAB) has 0 splits in our BioAtla stock split history database.
Looking at the BioAtla stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into BioAtla shares, starting with a $10,000 purchase of BCAB, presented on a split-history-adjusted basis factoring in the complete BioAtla stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
12/17/2020 |
|
End date: |
03/27/2024 |
|
Start price/share: |
$35.16 |
|
End price/share: |
$3.46 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-90.16% |
|
Average Annual Total Return: |
-50.75% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$983.89 |
|
Years: |
3.27 |
|
|
|
|
|